ImmunityBio Statistics
ImmunityBio (26CA) Stock Statistics & Valuation Metrics
Total Valuation
ImmunityBio has a market cap or net worth of EUR 5.86B. The enterprise value is EUR 10.97B.
- Market Cap
- EUR 5.86B
- Enterprise Value
- EUR 10.97B
Share Statistics
ImmunityBio has 1,063,826,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,063,826,000
- Owned by Insiders
- 61.92%
- Owned by Institutions
- 17.83%
Financial Efficiency
ImmunityBio’s return on equity (ROE) is 0.70 and return on invested capital (ROIC) is -56.95%.
- Return on Equity (ROE)
- 0.70
- Return on Assets (ROA)
- -0.70
- Return on Invested Capital (ROIC)
- -56.95%
- Return on Capital Employed (ROCE)
- -0.58
- Revenue Per Employee
- 164.66K
- Profits Per Employee
- -510.75K
- Employee Count
- 688
- Asset Turnover
- 0.23
- Inventory Turnover
- 0.83
Valuation Ratios
The current PE Ratio of ImmunityBio is -5.61. ImmunityBio’s PEG ratio is 0.05.
- PE Ratio
- -5.61
- PS Ratio
- 35.08
- PB Ratio
- -5.57
- Price to FCF
- -21.56
- Price to Operating Cash Flow
- -22.20
- PEG Ratio
- 0.05
Income Statement
In the last 12 months, ImmunityBio had revenue of 113.29M and earned -351.40M in profits. Earnings per share was -0.38.
- Revenue
- 113.29M
- Gross Profit
- 112.53M
- Operating Income
- -256.03M
- Pretax Income
- -351.61M
- Net Income
- -351.40M
- EBITDA
- -223.56M
- Earnings Per Share (EPS)
- -0.38
Cash Flow
In the last 12 months, operating cash flow was -287.56M and capital expenditures -9.53M, giving a free cash flow of -297.09M billion.
- Operating Cash Flow
- -287.56M
- Free Cash Flow
- -297.09M
- Free Cash Flow per Share
- -0.28
Dividends & Yields
ImmunityBio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.64%
- Earnings Yield
- -17.39%
Stock Price Statistics
- Beta
- 0.74
- 52-Week Price Change
- 220.80%
- 50-Day Moving Average
- 7.62
- 200-Day Moving Average
- 6.94
- Relative Strength Index (RSI)
- 27.43
- Average Volume (3m)
- 1,582
Important Dates
ImmunityBio upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
ImmunityBio as a current ratio of 5.10, with Debt / Equity ratio of -175.77%
- Current Ratio
- 5.10
- Quick Ratio
- 5.08
- Debt to Market Cap
- 0.46
- Net Debt to EBITDA
- -3.53
- Interest Coverage Ratio
- -2.28
Taxes
In the past 12 months, ImmunityBio has paid -135.00K in taxes.
- Income Tax
- -135.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
ImmunityBio EV to EBITDA ratio is -7.19, with an EV/FCF ratio of -24.33.
- EV to Sales
- 39.59
- EV to EBITDA
- -7.19
- EV to Free Cash Flow
- -24.33
- EV to Operating Cash Flow
- -25.14
Balance Sheet
ImmunityBio has EUR 334.33M in cash and marketable securities with EUR 869.52M in debt, giving a net cash position of -EUR 535.19M billion.
- Cash & Marketable Securities
- EUR 334.33M
- Total Debt
- EUR 869.52M
- Net Cash
- -EUR 535.19M
- Net Cash Per Share
- -EUR 0.50
- Tangible Book Value Per Share
- -EUR 1.09
Margins
Gross margin is 96.67%, with operating margin of -150.16%, and net profit margin of -607.79%.
- Gross Margin
- 96.67%
- Operating Margin
- -150.16%
- Pretax Margin
- -607.89%
- Net Profit Margin
- -607.79%
- EBITDA Margin
- -550.80%
- EBIT Margin
- -559.86%
Analyst Forecast
The average price target for ImmunityBio is EUR 12.93, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 12.93
- Price Target Upside
- 136.76% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 113.81%
- EPS Growth Forecast
- -146.92%
Scores
- Smart Score
- 9
- AI Score
- ―
